JP2013507366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507366A5 JP2013507366A5 JP2012533226A JP2012533226A JP2013507366A5 JP 2013507366 A5 JP2013507366 A5 JP 2013507366A5 JP 2012533226 A JP2012533226 A JP 2012533226A JP 2012533226 A JP2012533226 A JP 2012533226A JP 2013507366 A5 JP2013507366 A5 JP 2013507366A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- azetidin
- trifluoromethyl
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 49
- 125000001475 halogen functional group Chemical group 0.000 claims 46
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- -1 hydroxypropyl Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims 4
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- KREHFNPASISMLT-UHFFFAOYSA-N 1-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-4-methylsulfonylpiperazin-2-one Chemical compound O=C1CN(S(=O)(=O)C)CCN1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 KREHFNPASISMLT-UHFFFAOYSA-N 0.000 claims 2
- XDZADSVOHSQVTC-UHFFFAOYSA-N 1-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-4-methylsulfonylpiperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 XDZADSVOHSQVTC-UHFFFAOYSA-N 0.000 claims 2
- WUKRSOYOPHKYHF-UHFFFAOYSA-N 1-[3-fluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-4-methylsulfonylpiperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(C=C1F)=CC=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 WUKRSOYOPHKYHF-UHFFFAOYSA-N 0.000 claims 2
- QDMSPBCJVABTJI-UHFFFAOYSA-N 1-[4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-3,6-dihydro-2h-pyridin-1-yl]-2,2,2-trifluoroethanone Chemical compound FC1=CC(C=2CCN(CC=2)C(=O)C(F)(F)F)=CC(F)=C1OC(C1)CN1CC1=CC=C(C(F)(F)F)C=C1 QDMSPBCJVABTJI-UHFFFAOYSA-N 0.000 claims 2
- MVXRMNLRWSEVMF-UHFFFAOYSA-N 2-(4-methylsulfonylpiperazin-1-yl)-5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyrimidine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=NC=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 MVXRMNLRWSEVMF-UHFFFAOYSA-N 0.000 claims 2
- WXMFKKPOVWUMBQ-UHFFFAOYSA-N 2-[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanol Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(C(CO)C=2C=CC(=CC=2)C(F)(F)F)C1 WXMFKKPOVWUMBQ-UHFFFAOYSA-N 0.000 claims 2
- JKCDGKXUOWITEV-UHFFFAOYSA-N 2-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-4-(trifluoromethyl)-1,3-thiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2SC=C(N=2)C(F)(F)F)C1 JKCDGKXUOWITEV-UHFFFAOYSA-N 0.000 claims 2
- MFXBTDYTCIKRNZ-UHFFFAOYSA-N 2-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-5-(trifluoromethyl)pyrimidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2N=CC(=CN=2)C(F)(F)F)C1 MFXBTDYTCIKRNZ-UHFFFAOYSA-N 0.000 claims 2
- NZLZVERJPBTXAH-UHFFFAOYSA-N 2-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-4-(trifluoromethyl)-1,3-thiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2SC=C(N=2)C(F)(F)F)CC1 NZLZVERJPBTXAH-UHFFFAOYSA-N 0.000 claims 2
- TZQUXHRMXLPNIR-UHFFFAOYSA-N 3-(1,1-difluoroethyl)-5-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-1,2,4-oxadiazole Chemical compound CC(F)(F)C1=NOC(CN2CC(C2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 TZQUXHRMXLPNIR-UHFFFAOYSA-N 0.000 claims 2
- YRYBUIINEVJSKD-UHFFFAOYSA-N 3-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-5-propan-2-yl-1,2,4-oxadiazole Chemical compound O1C(C(C)C)=NC(CN2CC(C2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 YRYBUIINEVJSKD-UHFFFAOYSA-N 0.000 claims 2
- BPYCLQDOGIWCMA-UHFFFAOYSA-N 3-chloro-2-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-5-(trifluoromethyl)pyridine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C(=CC(=CN=2)C(F)(F)F)Cl)C1 BPYCLQDOGIWCMA-UHFFFAOYSA-N 0.000 claims 2
- BMLWMQDZZOGTFR-UHFFFAOYSA-N 3-cyclopropyl-5-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2ON=C(N=2)C2CC2)C1 BMLWMQDZZOGTFR-UHFFFAOYSA-N 0.000 claims 2
- ZEZKZGIIBXPWHM-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-(naphthalen-1-ylmethyl)azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C3=CC=CC=C3C=CC=2)C1 ZEZKZGIIBXPWHM-UHFFFAOYSA-N 0.000 claims 2
- YWPPYASFWVKDTH-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-(naphthalen-2-ylmethyl)azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=C3C=CC=CC3=CC=2)C1 YWPPYASFWVKDTH-UHFFFAOYSA-N 0.000 claims 2
- ZJOQZCRDOIEZFS-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[1-[4-(trifluoromethyl)phenyl]propyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(CC)N(C1)CC1OC(C(=C1)F)=C(F)C=C1C1CCN(S(C)(=O)=O)CC1 ZJOQZCRDOIEZFS-UHFFFAOYSA-N 0.000 claims 2
- HTGDOFSBHIEUIX-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound CN1N=C(C(F)(F)F)C=C1CN1CC(OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)C1 HTGDOFSBHIEUIX-UHFFFAOYSA-N 0.000 claims 2
- ZVDDYYQIYSBLBM-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]methyl]piperidin-4-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound CN1N=C(C(F)(F)F)C=C1CN1CCC(OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)CC1 ZVDDYYQIYSBLBM-UHFFFAOYSA-N 0.000 claims 2
- IXJJEYBHRVETLG-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(3-fluorooxetan-3-yl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=CC(=CC=2)C2(F)COC2)C1 IXJJEYBHRVETLG-UHFFFAOYSA-N 0.000 claims 2
- XFIYFKJEPMUAMR-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-(oxan-4-ylsulfonyl)piperidine Chemical compound FC1=CC(C2CCN(CC2)S(=O)(=O)C2CCOCC2)=CC(F)=C1OC(C1)CN1CC1=CC=C(C(F)(F)F)C=C1 XFIYFKJEPMUAMR-UHFFFAOYSA-N 0.000 claims 2
- UUDSTMMLSWAHBI-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 UUDSTMMLSWAHBI-UHFFFAOYSA-N 0.000 claims 2
- TXVWVMBVTQWPLT-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-piperidin-4-ylsulfonylpiperidine Chemical compound FC1=CC(C2CCN(CC2)S(=O)(=O)C2CCNCC2)=CC(F)=C1OC(C1)CN1CC1=CC=C(C(F)(F)F)C=C1 TXVWVMBVTQWPLT-UHFFFAOYSA-N 0.000 claims 2
- FKZSXTNYXOBXQG-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-pyrrolidin-3-ylsulfonylpiperidine Chemical compound FC1=CC(C2CCN(CC2)S(=O)(=O)C2CNCC2)=CC(F)=C1OC(C1)CN1CC1=CC=C(C(F)(F)F)C=C1 FKZSXTNYXOBXQG-UHFFFAOYSA-N 0.000 claims 2
- UINQQGMFVPCBAR-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)CC1 UINQQGMFVPCBAR-UHFFFAOYSA-N 0.000 claims 2
- ZQGKERQYOVCALX-UHFFFAOYSA-N 4-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2N=C(SC=2)C(F)(F)F)C1 ZQGKERQYOVCALX-UHFFFAOYSA-N 0.000 claims 2
- ILEKSOWVIGRTLK-UHFFFAOYSA-N 4-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-2-(trifluoromethyl)-1,3-thiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2N=C(SC=2)C(F)(F)F)CC1 ILEKSOWVIGRTLK-UHFFFAOYSA-N 0.000 claims 2
- FYPGJSOVVLGRIC-UHFFFAOYSA-N 4-methylsulfonyl-1-[5-[1-[[4-(trifluoromethoxy)phenyl]methyl]azetidin-3-yl]oxypyrazin-2-yl]piperazin-2-one Chemical compound O=C1CN(S(=O)(=O)C)CCN1C(N=C1)=CN=C1OC1CN(CC=2C=CC(OC(F)(F)F)=CC=2)C1 FYPGJSOVVLGRIC-UHFFFAOYSA-N 0.000 claims 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 2
- UHXGRLNXXIPHAK-UHFFFAOYSA-N 5-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2ON=C(N=2)C(F)(F)F)C1 UHXGRLNXXIPHAK-UHFFFAOYSA-N 0.000 claims 2
- PLROFIMLUNJEBN-UHFFFAOYSA-N 5-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(CN2CC(C2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 PLROFIMLUNJEBN-UHFFFAOYSA-N 0.000 claims 2
- RPZNXQJFTNRLGS-UHFFFAOYSA-N 5-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(CN2CCC(CC2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 RPZNXQJFTNRLGS-UHFFFAOYSA-N 0.000 claims 2
- WTIDTULUJMMFPP-UHFFFAOYSA-N 5-[[4-[2,6-difluoro-4-(4-fluoro-1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1(F)C(C=C1F)=CC(F)=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 WTIDTULUJMMFPP-UHFFFAOYSA-N 0.000 claims 2
- AEZSSFAWPPJUOE-UHFFFAOYSA-N 5-[[4-[2-fluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 AEZSSFAWPPJUOE-UHFFFAOYSA-N 0.000 claims 2
- FPPYBKDYHACVIJ-UHFFFAOYSA-N 5-[[4-[3-fluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C(=C1)F)=CC=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 FPPYBKDYHACVIJ-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000006001 difluoroethyl group Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- AHJAFRIFZRLGQO-UHFFFAOYSA-N 1-[5-[1-[(4-chlorophenyl)methyl]azetidin-3-yl]oxypyridin-2-yl]-4-methylsulfonylpiperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(Cl)=CC=2)C1 AHJAFRIFZRLGQO-UHFFFAOYSA-N 0.000 claims 1
- FTMFVDNBRISMBM-UHFFFAOYSA-N 1-[5-[1-[(4-methoxyphenyl)methyl]azetidin-3-yl]oxypyridin-2-yl]-4-methylsulfonylpiperazine Chemical compound C1=CC(OC)=CC=C1CN1CC(OC=2C=NC(=CC=2)N2CCN(CC2)S(C)(=O)=O)C1 FTMFVDNBRISMBM-UHFFFAOYSA-N 0.000 claims 1
- OOIYQDIPUYOXRM-UHFFFAOYSA-N 1-[5-[1-[(4-methylphenyl)methyl]azetidin-3-yl]oxypyridin-2-yl]-4-methylsulfonylpiperazine Chemical compound C1=CC(C)=CC=C1CN1CC(OC=2C=NC(=CC=2)N2CCN(CC2)S(C)(=O)=O)C1 OOIYQDIPUYOXRM-UHFFFAOYSA-N 0.000 claims 1
- JADXFOZAJSMQAV-UHFFFAOYSA-N 1-[5-[1-[[4-(difluoromethoxy)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]-4-methylsulfonylpiperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(OC(F)F)=CC=2)C1 JADXFOZAJSMQAV-UHFFFAOYSA-N 0.000 claims 1
- ZRKXJHNZKJRJIG-UHFFFAOYSA-N 1-methylsulfonyl-4-[4-[1-[(4-propan-2-ylphenyl)methyl]azetidin-3-yl]oxyphenyl]piperazine Chemical compound C1=CC(C(C)C)=CC=C1CN1CC(OC=2C=CC(=CC=2)N2CCN(CC2)S(C)(=O)=O)C1 ZRKXJHNZKJRJIG-UHFFFAOYSA-N 0.000 claims 1
- CRFIRNYALDVCNH-UHFFFAOYSA-N 1-methylsulfonyl-4-[5-[1-[(4-propan-2-ylphenyl)methyl]azetidin-3-yl]oxypyridin-2-yl]piperazine Chemical compound C1=CC(C(C)C)=CC=C1CN1CC(OC=2C=NC(=CC=2)N2CCN(CC2)S(C)(=O)=O)C1 CRFIRNYALDVCNH-UHFFFAOYSA-N 0.000 claims 1
- HJJNFIZAVLVPRN-UHFFFAOYSA-N 1-methylsulfonyl-4-[5-[1-[[3-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]piperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=C(C=CC=2)C(F)(F)F)C1 HJJNFIZAVLVPRN-UHFFFAOYSA-N 0.000 claims 1
- HTIAOECCZOFYCU-UHFFFAOYSA-N 1-methylsulfonyl-4-[5-[1-[[4-(trifluoromethoxy)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]piperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(OC(F)(F)F)=CC=2)C1 HTIAOECCZOFYCU-UHFFFAOYSA-N 0.000 claims 1
- NROQZUOLYKYDRH-UHFFFAOYSA-N 1-methylsulfonyl-4-[5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]piperazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 NROQZUOLYKYDRH-UHFFFAOYSA-N 0.000 claims 1
- FWNKUZCWCKOGKM-UHFFFAOYSA-N 1-propylsulfonyl-4-[5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]piperazine Chemical compound C1CN(S(=O)(=O)CCC)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 FWNKUZCWCKOGKM-UHFFFAOYSA-N 0.000 claims 1
- VUYPYGJFILRODH-UHFFFAOYSA-N 2-(4-methylsulfonylpiperazin-1-yl)-5-[1-[(4-propan-2-ylphenyl)methyl]azetidin-3-yl]oxypyrazine Chemical compound C1=CC(C(C)C)=CC=C1CN1CC(OC=2N=CC(=NC=2)N2CCN(CC2)S(C)(=O)=O)C1 VUYPYGJFILRODH-UHFFFAOYSA-N 0.000 claims 1
- BLPPBPZPVXKRKW-UHFFFAOYSA-N 2-(4-methylsulfonylpiperazin-1-yl)-5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyrazine Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CN=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 BLPPBPZPVXKRKW-UHFFFAOYSA-N 0.000 claims 1
- INSKWIQMYXYATL-UHFFFAOYSA-N 2-[[4-[5-(1-methylsulfonylpiperidin-4-yl)pyrazin-2-yl]oxypiperidin-1-yl]methyl]-4-(trifluoromethyl)-1,3-thiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(N=C1)=CN=C1OC1CCN(CC=2SC=C(N=2)C(F)(F)F)CC1 INSKWIQMYXYATL-UHFFFAOYSA-N 0.000 claims 1
- OBOIAHULPQYVNO-UHFFFAOYSA-N 3-(1,1-difluoroethyl)-5-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-1,2,4-oxadiazole Chemical compound CC(F)(F)C1=NOC(CN2CCC(CC2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 OBOIAHULPQYVNO-UHFFFAOYSA-N 0.000 claims 1
- GWTHCKYEDANWHJ-UHFFFAOYSA-N 3-(difluoromethyl)-5-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2ON=C(N=2)C(F)F)CC1 GWTHCKYEDANWHJ-UHFFFAOYSA-N 0.000 claims 1
- HQIIRGCOGOMVGR-UHFFFAOYSA-N 3-[4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]piperidin-1-yl]sulfonylpropan-1-ol Chemical compound C1CN(S(=O)(=O)CCCO)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 HQIIRGCOGOMVGR-UHFFFAOYSA-N 0.000 claims 1
- AWYYPLHYBDRNQW-UHFFFAOYSA-N 3-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CN(CC=2N=C(ON=2)C(F)(F)F)C1 AWYYPLHYBDRNQW-UHFFFAOYSA-N 0.000 claims 1
- YIEOSBYCFGPQQE-UHFFFAOYSA-N 3-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-5-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2N=C(ON=2)C(F)(F)F)CC1 YIEOSBYCFGPQQE-UHFFFAOYSA-N 0.000 claims 1
- CJRXUJPBCUWSLT-UHFFFAOYSA-N 3-tert-butyl-5-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NOC(CN2CC(C2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 CJRXUJPBCUWSLT-UHFFFAOYSA-N 0.000 claims 1
- QSSTWCWREAWYBO-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[1-[4-(trifluoromethyl)phenyl]ethyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(C)N(C1)CC1OC(C(=C1)F)=C(F)C=C1C1CCN(S(C)(=O)=O)CC1 QSSTWCWREAWYBO-UHFFFAOYSA-N 0.000 claims 1
- NCKOVDFANVCCCR-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[1-[4-(trifluoromethyl)phenyl]propan-2-yl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1C(OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)CN1C(C)CC1=CC=C(C(F)(F)F)C=C1 NCKOVDFANVCCCR-UHFFFAOYSA-N 0.000 claims 1
- IPSWMTDIRGLRFN-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[2-methyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound CN1N=C(C(F)(F)F)N=C1CN1CC(OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)C1 IPSWMTDIRGLRFN-UHFFFAOYSA-N 0.000 claims 1
- JYQLNIAYJXPRLF-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[2-methyl-5-(trifluoromethyl)-1,2,4-triazol-3-yl]methyl]piperidin-4-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound CN1N=C(C(F)(F)F)N=C1CN1CCC(OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)CC1 JYQLNIAYJXPRLF-UHFFFAOYSA-N 0.000 claims 1
- SOQHVOHGNJCARW-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[3-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2C=C(C=CC=2)C(F)(F)F)CC1 SOQHVOHGNJCARW-UHFFFAOYSA-N 0.000 claims 1
- TXSSQJHMVOARHI-UHFFFAOYSA-N 4-[3,5-difluoro-4-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonyl-3,6-dihydro-2h-pyridine Chemical compound C1N(S(=O)(=O)C)CCC(C=2C=C(F)C(OC3CN(CC=4C=CC(=CC=4)C(F)(F)F)C3)=C(F)C=2)=C1 TXSSQJHMVOARHI-UHFFFAOYSA-N 0.000 claims 1
- HIMHPDQNBWRSAK-UHFFFAOYSA-N 4-[3,5-difluoro-4-[3-methyl-1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxyphenyl]-1-methylsulfonylpiperidine Chemical compound C1C(C)(OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)CN1CC1=CC=C(C(F)(F)F)C=C1 HIMHPDQNBWRSAK-UHFFFAOYSA-N 0.000 claims 1
- FSVQMSDKVKBPQA-UHFFFAOYSA-N 4-methylsulfonyl-1-[5-[1-[(4-propan-2-ylphenyl)methyl]azetidin-3-yl]oxypyrazin-2-yl]piperazin-2-one Chemical compound C1=CC(C(C)C)=CC=C1CN1CC(OC=2N=CC(=NC=2)N2C(CN(CC2)S(C)(=O)=O)=O)C1 FSVQMSDKVKBPQA-UHFFFAOYSA-N 0.000 claims 1
- HICIFGBVONFQQZ-UHFFFAOYSA-N 4-methylsulfonyl-1-[5-[1-[(4-propan-2-ylphenyl)methyl]azetidin-3-yl]oxypyridin-2-yl]piperazin-2-one Chemical compound C1=CC(C(C)C)=CC=C1CN1CC(OC=2C=NC(=CC=2)N2C(CN(CC2)S(C)(=O)=O)=O)C1 HICIFGBVONFQQZ-UHFFFAOYSA-N 0.000 claims 1
- NKJQSXQYAYBVAC-UHFFFAOYSA-N 4-methylsulfonyl-1-[5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyrazin-2-yl]piperazin-2-one Chemical compound O=C1CN(S(=O)(=O)C)CCN1C(N=C1)=CN=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 NKJQSXQYAYBVAC-UHFFFAOYSA-N 0.000 claims 1
- FJUMKFRWGGTZEC-UHFFFAOYSA-N 4-methylsulfonyl-1-[5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]piperazin-2-one Chemical compound O=C1CN(S(=O)(=O)C)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 FJUMKFRWGGTZEC-UHFFFAOYSA-N 0.000 claims 1
- XBIALPHDDHGCCI-UHFFFAOYSA-N 4-propylsulfonyl-1-[5-[1-[[4-(trifluoromethyl)phenyl]methyl]azetidin-3-yl]oxypyridin-2-yl]piperazin-2-one Chemical compound O=C1CN(S(=O)(=O)CCC)CCN1C(N=C1)=CC=C1OC1CN(CC=2C=CC(=CC=2)C(F)(F)F)C1 XBIALPHDDHGCCI-UHFFFAOYSA-N 0.000 claims 1
- ZGPRBKMQVAYTCL-UHFFFAOYSA-N 5-[[4-[2,3-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C(=C1F)F)=CC=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 ZGPRBKMQVAYTCL-UHFFFAOYSA-N 0.000 claims 1
- WZKXEORDWPFSSG-UHFFFAOYSA-N 5-[[4-[2,5-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C(=C1)F)=CC(F)=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 WZKXEORDWPFSSG-UHFFFAOYSA-N 0.000 claims 1
- KDQZKWKCRHXONL-UHFFFAOYSA-N 5-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-2-(trifluoromethyl)pyridine Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2C=NC(=CC=2)C(F)(F)F)CC1 KDQZKWKCRHXONL-UHFFFAOYSA-N 0.000 claims 1
- GOAIPAPWWLKQTR-UHFFFAOYSA-N 5-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(2-fluoropropan-2-yl)-1,2,4-oxadiazole Chemical compound CC(C)(F)C1=NOC(CN2CCC(CC2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 GOAIPAPWWLKQTR-UHFFFAOYSA-N 0.000 claims 1
- LDFDAFNOLBHDHI-UHFFFAOYSA-N 5-[[4-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1F)=CC(F)=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 LDFDAFNOLBHDHI-UHFFFAOYSA-N 0.000 claims 1
- SAGRJUDCRNGPCR-UHFFFAOYSA-N 5-[[4-[3,5-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C(=C1)F)=C(F)C=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 SAGRJUDCRNGPCR-UHFFFAOYSA-N 0.000 claims 1
- DECUEDJKHPAOEF-UHFFFAOYSA-N 5-[[4-[4-(1-methylsulfonylpiperidin-4-yl)phenoxy]piperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCC1C(C=C1)=CC=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 DECUEDJKHPAOEF-UHFFFAOYSA-N 0.000 claims 1
- PTWSXKXZUIBSQO-UHFFFAOYSA-N 5-[[4-[5-(4-methylsulfonylpiperazin-1-yl)pyrazin-2-yl]oxypiperidin-1-yl]methyl]-3-(trifluoromethyl)-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)C)CCN1C(N=C1)=CN=C1OC1CCN(CC=2ON=C(N=2)C(F)(F)F)CC1 PTWSXKXZUIBSQO-UHFFFAOYSA-N 0.000 claims 1
- HJTHQHQRLYFGEK-UHFFFAOYSA-N 5-tert-butyl-3-[[3-[2,6-difluoro-4-(1-methylsulfonylpiperidin-4-yl)phenoxy]azetidin-1-yl]methyl]-1,2,4-oxadiazole Chemical compound O1C(C(C)(C)C)=NC(CN2CC(C2)OC=2C(=CC(=CC=2F)C2CCN(CC2)S(C)(=O)=O)F)=N1 HJTHQHQRLYFGEK-UHFFFAOYSA-N 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- GDTCWJFNPYUGAI-UHFFFAOYSA-N CS(N(CC=CC1)C1C(C=C1F)=CC(F)=C1OC1CN(CC2=CC=C(C(F)(F)F)C=C2)C1)(=O)=O Chemical compound CS(N(CC=CC1)C1C(C=C1F)=CC(F)=C1OC1CN(CC2=CC=C(C(F)(F)F)C=C2)C1)(=O)=O GDTCWJFNPYUGAI-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 230000004140 ketosis Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 201000000484 premenstrual tension Diseases 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZMLHBBXPXZXTSP-UHFFFAOYSA-N 2-fluoropropane Chemical group C[C](C)F ZMLHBBXPXZXTSP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25042409P | 2009-10-09 | 2009-10-09 | |
| US61/250,424 | 2009-10-09 | ||
| US36511210P | 2010-07-16 | 2010-07-16 | |
| US61/365,112 | 2010-07-16 | ||
| PCT/US2010/051186 WO2011044001A1 (en) | 2009-10-09 | 2010-10-01 | Compounds and compositions as modulators of gpr119 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507366A JP2013507366A (ja) | 2013-03-04 |
| JP2013507366A5 true JP2013507366A5 (enExample) | 2013-11-14 |
Family
ID=43033382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533226A Pending JP2013507366A (ja) | 2009-10-09 | 2010-10-01 | Ｇｐｒ１１９活性モジュレーターとしての化合物および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8575168B2 (enExample) |
| EP (1) | EP2486033A1 (enExample) |
| JP (1) | JP2013507366A (enExample) |
| KR (1) | KR20120092629A (enExample) |
| CN (1) | CN102686579A (enExample) |
| AR (1) | AR078550A1 (enExample) |
| AU (1) | AU2010303780B2 (enExample) |
| BR (1) | BR112012008004A2 (enExample) |
| CA (1) | CA2774573A1 (enExample) |
| EA (1) | EA201200570A1 (enExample) |
| IN (1) | IN2012DN02471A (enExample) |
| MX (1) | MX2012004078A (enExample) |
| TW (1) | TW201124400A (enExample) |
| UY (1) | UY32937A (enExample) |
| WO (1) | WO2011044001A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0911118A2 (pt) * | 2008-04-07 | 2015-10-06 | Irm Llc | composto e compisições como moduladores de atividade de gpr119 |
| GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
| AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP2015523404A (ja) | 2012-08-02 | 2015-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 |
| WO2014052619A1 (en) * | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
| EA201590953A1 (ru) * | 2012-11-16 | 2015-08-31 | Бристол-Майерс Сквибб Компани | Пирролидиновые модуляторы gpr40 |
| ES2907461T3 (es) * | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| AR110988A1 (es) | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| KR20200125758A (ko) | 2017-10-27 | 2020-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 피리딘 카보닐 유도체 및 trpc6 억제제로서 이의 치료학적 용도 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB284425A (en) | 1926-11-22 | 1928-02-02 | James Last | Improvements in and relating to sand or like moulds for making castings |
| JPS5612114B2 (enExample) | 1974-06-07 | 1981-03-18 | ||
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
| CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
| JPS60149573A (ja) | 1984-01-13 | 1985-08-07 | Mitsubishi Petrochem Co Ltd | フエニル尿素誘導体 |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| HU198005B (en) | 1984-12-04 | 1989-07-28 | Sandoz Ag | Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them |
| US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| AU598775B2 (en) | 1985-10-25 | 1990-07-05 | Sandoz Ag | Heterocyclic analogs of mevalonolactone |
| FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
| DK277488A (da) | 1987-05-22 | 1988-11-23 | Squibb & Sons Inc | Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen |
| US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
| JP2969359B2 (ja) * | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
| US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| JP2000502086A (ja) | 1995-12-13 | 2000-02-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 核レセプターのリガンドおよびリガンド結合ドメイン |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP1562956A4 (en) | 2002-11-22 | 2007-10-10 | Japan Tobacco Inc | HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| EP2316827B1 (en) | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| JP2008545010A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇタンパク質共役受容体アゴニスト |
| JP2009521448A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| JP5330260B2 (ja) * | 2006-12-06 | 2013-10-30 | スミスクライン ビーチャム コーポレーション | 二環式化合物ならびに抗糖尿病薬としての使用 |
| ES2499018T3 (es) * | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| GB0720390D0 (en) * | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) * | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| BRPI0911118A2 (pt) * | 2008-04-07 | 2015-10-06 | Irm Llc | composto e compisições como moduladores de atividade de gpr119 |
-
2010
- 2010-10-01 CA CA2774573A patent/CA2774573A1/en not_active Abandoned
- 2010-10-01 MX MX2012004078A patent/MX2012004078A/es active IP Right Grant
- 2010-10-01 EA EA201200570A patent/EA201200570A1/ru unknown
- 2010-10-01 BR BR112012008004A patent/BR112012008004A2/pt not_active IP Right Cessation
- 2010-10-01 CN CN2010800453177A patent/CN102686579A/zh active Pending
- 2010-10-01 IN IN2471DEN2012 patent/IN2012DN02471A/en unknown
- 2010-10-01 AU AU2010303780A patent/AU2010303780B2/en not_active Ceased
- 2010-10-01 KR KR1020127011865A patent/KR20120092629A/ko not_active Abandoned
- 2010-10-01 US US12/896,735 patent/US8575168B2/en not_active Expired - Fee Related
- 2010-10-01 JP JP2012533226A patent/JP2013507366A/ja active Pending
- 2010-10-01 WO PCT/US2010/051186 patent/WO2011044001A1/en not_active Ceased
- 2010-10-01 EP EP10763952A patent/EP2486033A1/en not_active Withdrawn
- 2010-10-07 AR ARP100103648A patent/AR078550A1/es unknown
- 2010-10-08 TW TW099134498A patent/TW201124400A/zh unknown
- 2010-10-08 UY UY0001032937A patent/UY32937A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI358409B (en) | Heteroaryl substituted piperidine derivatives | |
| JP2006518763A5 (enExample) | ||
| AU2010303780B2 (en) | Compounds and compositions as modulators of GPR119 activity | |
| US9763957B2 (en) | Autotaxin inhibitors | |
| US7678796B2 (en) | MGluR5 modulators I | |
| US9150575B2 (en) | Piperidinylpyrazolopyridine derivative | |
| JP2012528847A5 (enExample) | ||
| EP2556056A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
| TW201038586A (en) | Sulfonamide derivatives | |
| RU2009147733A (ru) | Пиридилпиперидновые антагонисты рецептора орексинов | |
| EA018703B1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| WO2010099054A2 (en) | Soluble guanylate cyclase activators | |
| RU2010115260A (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| KR20110130476A (ko) | 대사성 장애의 치료용 화합물 | |
| JP2017512184A5 (enExample) | ||
| WO2012117996A1 (ja) | Ｇｐｒ１１９作動薬 | |
| WO2012145361A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
| WO2013055910A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
| WO2012170702A1 (en) | Modulators of the gpr119 receptor and the treatment of disorders related thereto | |
| JP2008513405A5 (enExample) | ||
| CN1980912A (zh) | 吡唑衍生物 | |
| JP2014001144A (ja) | Ｇｐｒ１１９作動薬 | |
| AU2016289079A1 (en) | Novel imide derivatives and use thereof as medicine | |
| WO2025224512A1 (ko) | Hsd17b13 (17-beta-hydroxysteroid dehydrogenase 13) 억제제로서 신규 화합물 및 이를 포함하는 약학적 조성물 | |
| TH128615A (th) | สารประกอบและองค์ประกอบในฐานะตัวคุมของการทำหน้าที่ gpr119 |